Background. Previous thoracic artificial lungs (TALs) had blood flow impedance greater than that of the natural lungs, which could cause abnormal pulmonary hemodynamics. New compliant TALs (cTALs), however, have an impedance lower than that of the natural lung.
and then travels through the outlet manifold and exits through the outlet conduit. To create the fiber bundle, woven mats of polypropylene fibers with a fiber diameter of 210 m were wound into compact bundles with porosity, path length, and frontal area of 0.75, 0.038, and 0.013 m 2 , respectively.
Experimental Procedure
A total of 5 male sheep averaging 60.2 Ϯ 1.9 kg were used in this study. All sheep received humane care in compliance with the Guide for the Care and Use of Laboratory Animals, and all methods were approved by the University of Michigan Committee for the Use and Care of Animals. Anesthesia was induced with 6 to 9 mL/kg of propofol and was then maintained after endotracheal intubation with 1% to 3% inhaled isoflurane. Sheep were mechanically ventilated with O 2 using a Narkomed 6000 ventilator (North American Dräger, Telford, PA). The ventilator was set to a tidal volume of 10 mL/kg and a frequency of 12 breaths/min and was adjusted to maintain a Paco 2 between 35 and 45 mm Hg. A carotid arterial line and left jugular venous line were placed and then connected to fluid-coupled pressure transducers (Hospira, Inc, Lake Forest, IL) for the continuous monitoring of arterial and central venous pressures (P Art and P CV ). A muscle-sparing left thoracotomy was performed and the main PA and LA were identified. Polyester vascular grafts (Terumo, Ann Arbor, MI) for artificial lung attachment were attached to the PA (between the pulmonary valve and the bifurcation) and LA. An ultrasonic perivascular flow probe (Transonic 24AX; Transonic Systems, Inc, Ithaca, NY) was placed around the PA proximal to the device inlet graft. This probe was connected to a flow meter (T400; Transonic Systems, Inc) to allow for the measurement of PA flow (Q PA ). A pressure catheter (Becton Dickinson and Co, Franklin Lakes, NJ) was then inserted at the proximal PA and connected to a transducer for the display and recording of the PA pressure (P PA ). A Rommel tourniquet was placed around the distal PA to allow for the adjustment of flow through the cTAL. Before device attachment, 1g of methylprednisolone was administered, and the animal was anticoagulated with 100 IU/kg of intravenous sodium heparin to maintain active clotting times of greater than 300 seconds.
The cTAL was primed with heparanized saline (10 U/mL) and then connected to the PA (device inlet) and LA (device outlet) grafts (Fig 2) . An ultrasonic flow probe (Transonic 14PXL; Transonic Systems, Inc) was placed around the inflow conduit and connected to a flow meter (T400; Transonic Systems, Inc) to measure device flow (Q cTAL ). Pressure transducers were connected to the device inlet and outlet to acquire device inlet and outlet pressure (P in and P out ). A suction line was attached to the cTAL gas outlet and 95%:5% O 2 :CO 2 with 2% to 3% vaporized isoflurane was used as the sweep gas through the gas inlet. Sweep gas flow was adjusted during cTAL use to maintain Paco 2 between 35 and 45 mm Hg. A Hoffmann clamp was placed around the cTAL outlet conduit to restrict flow through the device. After cTAL attachment, clamps on the cTAL inlet and outlet conduits were removed, and the Hoffmann clamp was slowly loosened until Q cTAL ϭ 1 L/min was achieved. This flow was maintained for 10 minutes for equilibration of fluid volumes and any inflammatory response. After device attachment, central venous pressure (CVP) decreased related to the systemic inflammatory response, and 500 mL of hetastarch and 500 to 1000 mL of crystalloid were administered to restore CVP back to baseline values. Thereafter, the device conduits were clamped off and baseline data was obtained, marking the start of the experiment.
A hemodynamic data set of Q PA , Q cTAL , P art , P CV , P PA , P in , P out was digitally acquired for 10 seconds at a sampling frequency of 250 Hz through a BIOPAC data acquisition system (BIOPAC, Goleta, CA). Before attaching the cTAL, an animal baseline data set was acquired. Rest and exercise conditions were simulated using a continuous dobutamine infusion of 0 g/kg/min and then 5 g/kg/min, respectively. At each dose, the hemodynamic data set was acquired at baseline (Q cTAL ϭ 0 L/min) and conditions of 60%, 75%, and 90% of CO shunted to the cTAL (100 * Q cTAL /Q PA ), created by tight- 
Abbreviations and Acronyms
CO ϭ cardiac output cTAL ϭ compliant thoracic artificial lung CVP ϭ central venous pressure LA ϭ left atrium MAP ϭ mean arterial pressure mPAPϭ mean pulmonary artery pressure PA ϭ pulmonary artery PVR ϭ pulmonary vascular resistance RV ϭ right ventricle TAL ϭ thoracic artificial lung Z 0 ϭ zeroth harmonic pulmonary input impedance ening the Rommel tourniquet around the PA. At each condition, 10 minutes was allowed for equilibration before data were obtained. Also, at each condition, a device exit gas sample was taken along with blood samples from the animal, device inlet, and device outlet.
Data Analysis
The zeroth harmonic pulmonary input impedance modulus, Z 0 , was calculated at each flow condition:
where P 0 is the mean PA pressure and Q 0 is the mean PA blood flow rate. Device resistance, R, was calculated using the formula:
where P in is the cTAL inlet pressure, P out is the cTAL outlet pressure, and Q cTAL is cTAL 
Results

Animal Physiology
Before Without dobutamine, Z 0 remained below baseline at all conditions. At 5 g/kg/min of dobutamine, baseline Z 0 decreased because of increased blood flow to the natural lungs. As more flow was diverted to the TAL, Z 0 was initially relatively constant but began to rise at 75% flow. As the natural lung was increasingly excluded, Z 0 then rose toward the same Z 0 as without dobutamine. At 90% flow, Z 0 had increased to 50% greater than the 5 g/kg/ min dobutamine baseline and was almost equivalent to all 0 g/kg/min conditions. This increase was significant (p ϭ 0.049) when compared with baseline.
MAP and mPAP for both dobutamine levels are displayed in Table 1 Table 2 for each device flow condition. The device outlet oxyhemoglobin saturations were greater than 99% at every flow condition, although venous conditions were not sufficient to challenge the device. A typical hemoglobin and device inlet Po 2 was 7.5 and 80 mm Hg, respectively. Even with this higher inlet Po 2 , Vo 2 rates ranged from 85.7 Ϯ 7.7 mL/min at 0 g/kg/min dobutamine and 60% CO to the cTAL to 155.5 Ϯ 8.8 mL/min at 5 g/kg/min dobutamine and 90% CO to the cTAL. Finally, at the conclu- 
Comment
To date, there is no commercially available TAL. Over 18 years of development, these devices have always featured excellent gas exchange, and research has thus focused on developing devices with progressively lower blood flow resistance and improved hemodynamics during in vivo attachment [7] [8] [9] . Ideally, TALs should be able to provide the majority of the gas exchange while being able to maintain normal pulmonary hemodynamics.
Because there is no commercial device for this application, a few groups have investigated clinical PA-LA attachment in cases of severe pulmonary hypertension using the lowest resistance gas exchanger on the market, the Novalung ILA (NovaLung, Heilbronn, Germany). Two patients treated this way had primary pulmonary hypertension and 4 had pulmonary venoocclusive disease. Five of the patients (87%) underwent successful bridging to transplantation. Despite this success, the Novalung was not designed for this application. Its intended use is arteriovenous CO 2 removal, which features much lower blood flow of 2 L/min and higher driving pressures. As a result, the Novalung's gas exchange capabilities are low for the application, and the resistance is approximately 5 to 6 mm Hg/(L/min) at blood flow of 2 to 2.5 L/min [10 -12] . To support patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and sepsis, greater gas exchange will be required. Moreover, in cases of marked pulmonary hypertension, it would be ideal to be able to fully unload the RV and eliminate the need for inotropic agents.
In the current study, the new cTAL design was tested in healthy animals with normal PA pressure. Therefore, the goal for this study was to maintain normal PA pressures and CO with up to 90% of CO diverted to the cTAL. Results indicate that these goals were met. cTAL attachment caused only minimal, statistically insignificant decreases in CO and increases in PA pressure from baseline at all conditions. At the most extreme condition, simulated exercise with 90% of the CO diverted to the cTAL, CO decreased 5.6% and PA pressure increased 8.8 mm Hg. This, however, represents an extreme case. A more typical, and advisable [13] , condition would likely be 75% of CO. In this case, CO was identical to baseline values, and PA pressure decreased at rest and increased a small amount during simulated exercise.
Maintenance of normal pulmonary hemodynamics was the result of very low cTAL resistance. Average resistance for the range of flows tested was 0.51 Ϯ 0.01 Z 0 increases [5, 6, 14] . In this study, Z 0 was lower than baseline at 60% flow to the cTAL because of the second parallel flow path provided by the cTAL and the minimal banding of the PA at that condition. As the PA was banded further, the natural lung portion of the system was closed, the percentage of flow to the cTAL increased, and Z 0 increased slightly. However, since device resistance remained low, the resulting Z 0 remained small and similar to that of healthy natural lungs. At 5 g/kg/min of dobutamine, however, high CO and PA pressure led to lower baseline Z 0 . As flow was diverted to the cTAL, Z 0 then increased to the same level seen in the case of 0 g/kg/min dobutamine.
Based on these results, the cTAL will be able to completely unload the RV in vivo during PA-LA attachment in patients with any degree of pulmonary hypertension. To examine this, one can use the equation P PA ϭ CO * R ϩ P LA , where P PA is the PA pressure, P LA is the left atrial pressure, and CO is cardiac output. R is the resistance of the parallel artificial lung and the natural lung Ultimately, this study suggests that the cTAL is capable of being used clinically in parallel with the native lungs and under high-flow conditions. Minimal decreases in CO were seen at 90% flow to the device at both dobutamine levels, indicating exercise would be possible during cTAL attachment. Since cTAL resistance is small, flow should route preferentially through the device. This attachment mode could be used in any patient with chronic respiratory insufficiency but would be ideal for patients with high pulmonary vascular resistance (PVR) because the device resistance would be much lower than the native lung resistance. Approximately 57% of CO went through the cTAL with no PA banding in these sheep with normal PVR. Assuming PVR ϭ 2.25 mm Hg/(L/min) in patients with pulmonary hypertension, about 70% of the CO would flow through the cTAL with no PA banding.
Further long-term testing (Ն 14 days) of in-parallel attachment of the cTAL is necessary in healthy sheep and sheep with pulmonary hypertension. These studies would focus on the biocompatibility of the device in a fashion similar to the studies of Sato and colleagues [16, 17] with the Biolung. Those studies used simple heparin anticoagulation with active clotting times (ACTs) from 180 to 220 seconds. That said, future studies with this device should examine various surface coatings as well as different anticoagulation strategies, including aspirin to inhibit platelets as is sometimes used with the Novalung ILA [10] . Although farm sheep tend to be more procoagulant than humans, these studies may help to define clinical anticoagulation strategies.
In conclusion, the cTAL resistance is lower than the natural lung, averaging 0.51 Ϯ 0.03 mm Hg/(L/min). Use of the cTAL in a PA-LA configuration caused no change in CO under rest and exercise conditions. Thus the cTAL can provide PA-LA respiratory support without significant changes in pulmonary hemodynamics in healthy sheep and will be capable of unloading the RV in patients with pulmonary hypertension.
